XRad Therapeutics

XRad Therapeutics is a privately held clinical-stage biopharmaceutical company focused on developing dual kinase inhibitors for the treatment of cancer. The company’s lead candidate, XRD-0394, is a first-in-class oral dual kinase inhibitor that simultaneously inhibits Ataxia Telangiectasia Mutated (ATM) and DNA-dependent protein kinase (DNA-PK), designed to enhance the effectiveness of radiotherapy based on preclinical studies.